Zenas BioPharma (ZBIO) Stock Analysis: AI Score & Alternative Data
Zenas BioPharma — alt-data steady across 90 days
Is Zenas BioPharma a buy right now? The alternative data says hold. This ZBIO stock analysis is built on the 25+ alternative data signals AltIndex tracks on Zenas BioPharma every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 46/100: a Hold. The stock trades at $26.94 with a $2B market cap.
No core signal has moved more than 5% in 90 days — steady, but without the momentum that pushes a stock into buy territory.
ZBIO’s broader alt-data profile also covers job postings (10 open roles), headcount (207 employees, according to LinkedIn), and web traffic (11K monthly visits). Every signal links to its own page with full history, the ZBIO technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on ZBIO is just below.
Zenas BioPharma AI Stock Analysis
Zenas BioPharma is a leading biotechnology company specializing in the development and commercialization of innovative therapeutics. With a focus on addressing unmet medical needs, Zenas BioPharma is dedicated to improving patient outcomes through cutting-edge research and robust clinical trials.
Analysis generated September 29, 2026.
Recent Zenas BioPharma Stock Alerts
|
Zenas BioPharma | October 1 Price is up by 6% in the last 24h. |
|
Zenas BioPharma | September 24 Price is down by -7.1% in the last 24h. |
|
Zenas BioPharma | September 23 Price is down by -6.1% in the last 24h. |
|
Zenas BioPharma | August 25 Price is up by 6% in the last 24h. |
Zenas BioPharma Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 11K | N/A | |
| Job Posts | 10 | N/A | |
| LinkedIn Employees | 207 | N/A | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 15 | N/A | |
| Stocktwits Mentions | 3 | 200.0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 800 | N/A |
About Zenas BioPharma (ZBIO)
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. The company is headquartered in Waltham, Massachusetts.
| Price | $26.94 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $2B |
| Year Range | $15 – $43 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Zenas BioPharma News
View more → |
Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn?September 23 - Yahoo Entertainment |
 |
Bispecifics Market to Gain Momentum During the Forecast Period (2026-2036) with Expanding Pipeline and Increasing Therapeutic Adoption | DelveInsightSeptember 14 - PRNewswire |
See Zenas BioPharma’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for ZBIO, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEZenas BioPharma Earnings & Financial Performance
View all earnings →Zenas BioPharma Insider Trading Activity
View all →| MOULDER LEON O JR filed to sell 96,928 shares at $0.0. May 18 '26 |
| MOULDER LEON O JR filed to sell 1,786,039 shares at $0.0. Apr 29 '26 |
| MOULDER LEON O JR filed to sell 1,751,039 shares at $0.0. Apr 28 '26 |
| Lu Hongbo filed to sell 426,736 shares at $0.0. Mar 31 '26 |
| Lu Hongbo filed to sell 422,968 shares at $0.0. Mar 31 '26 |
Zenas BioPharma Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Zenas BioPharma
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
ZymeworksZYME |
$25.65 2.1% | $2B | 41 |
 |
Sarepta TherapeuticsSRPT |
$17.31 1.0% | $2B | 44 |
 |
PersonalisPSNL |
$16.03 2.3% | $2B | 52 |
 |
AbsciABSI |
$10.27 10.9% | $2B | 49 |
 |
NovavaxNVAX |
$11.32 9.9% | $2B | 43 |
Explore Zenas BioPharma Data
Frequently Asked Questions: Zenas BioPharma (ZBIO)
Zenas BioPharma has an AltIndex AI Score of 46/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
46/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Zenas BioPharma (ZBIO) stock is $26.94 with a market cap of $2B.
As of today, Zenas BioPharma’s PE (Price to Earnings) ratio is —.
View the latest Zenas BioPharma insider transactions to see recent buying and selling activity by company executives and directors.
Check the Zenas BioPharma congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The ZBIO stock price chart above shows Zenas BioPharma’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Zenas BioPharma technical analysis for RSI, moving averages, and more.
See the stocks similar to Zenas BioPharma section on this page for companies in the same industry ranked by market cap and AI Score.
